Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Eq save search
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
EQ | $1.77 -1.12% -1.13% 74K
|
Health Technology
|
| O: -1.73%
H: 0.0%
C: -7.05%
lupus positive topline study
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
Published: 2023-11-13 (Crawled : 17:00) - biospace.com/
EQ | $1.77 -1.12% -1.13% 74K
|
Health Technology
|
| O: 0.08%
H: 6.43%
C: 0.81%
positive meeting study
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
Published: 2022-09-27 (Crawled : 12:00) - biospace.com/
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 6.83%
H: 13.66%
C: 10.88%
EQ | $1.77 -1.12% -1.13% 74K
|
Health Technology
|
| O: 15.54%
H: 14.35%
C: 6.28%
lupus positive results study
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
Published: 2021-12-13 (Crawled : 13:30) - biospace.com/
EQ | $1.77 -1.12% -1.13% 74K
|
Health Technology
|
| O: -0.21%
H: 0.95%
C: -2.11%
disease positive
EHA Updates: Companies Share Positive Data in Different Blood Disorders
Published: 2021-06-11 (Crawled : 18:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.13%
H: 0.11%
C: -0.09%
EQ | $1.77 -1.12% -1.13% 74K
|
Health Technology
|
| O: -6.16%
H: 0.31%
C: -6.41%
blood positive
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
EQ | $1.77 -1.12% -1.13% 74K
|
Health Technology
|
| O: -6.16%
H: 0.31%
C: -6.41%
disease treatment positive results topline
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association
Published: 2021-05-13 (Crawled : 12:15) - globenewswire.com
EQ | $1.77 -1.12% -1.13% 74K
|
Health Technology
|
| O: 3.72%
H: 5.28%
C: -0.94%
presentation disease europe positive
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
Published: 2021-03-15 (Crawled : 12:00) - globenewswire.com
EQ | $1.77 -1.12% -1.13% 74K
|
Health Technology
|
| O: 3.03%
H: 6.75%
C: 1.84%
presentation disease blood positive
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
Published: 2021-02-12 (Crawled : 20:03) - globenewswire.com
EQ | $1.77 -1.12% -1.13% 74K
|
Health Technology
| Email alert
Add to watchlist
disease treatment positive therapy
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.